Neoleukin Therapeutics (NLTX) Competitors $19.99 +0.24 (+1.22%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. TNGX, STOK, PHAT, AMLX, BGM, GYRE, SANA, MRVI, DNA, and SIGAShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), BGM Group (BGM), Gyre Therapeutics (GYRE), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Ginkgo Bioworks (DNA), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Tango Therapeutics Stoke Therapeutics Phathom Pharmaceuticals Amylyx Pharmaceuticals BGM Group Gyre Therapeutics Sana Biotechnology Maravai LifeSciences Ginkgo Bioworks Siga Technologies Tango Therapeutics (NASDAQ:TNGX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk. Which has better earnings and valuation, TNGX or NLTX? Neoleukin Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M17.76-$130.30M-$1.33-5.05Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.43 Is TNGX or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -599.11%. Neoleukin Therapeutics' return on equity of -37.22% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-599.11% -79.72% -49.30% Neoleukin Therapeutics N/A -37.22%-30.91% Do analysts prefer TNGX or NLTX? Tango Therapeutics currently has a consensus target price of $10.50, indicating a potential upside of 56.37%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tango Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in TNGX or NLTX? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 7.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, TNGX or NLTX? Tango Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Does the media prefer TNGX or NLTX? In the previous week, Tango Therapeutics had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for Tango Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Tango Therapeutics' score of -0.20 indicating that Neoleukin Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tango Therapeutics Neutral Neoleukin Therapeutics Neutral SummaryTango Therapeutics beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.87M$837.12M$5.76B$9.75BDividend YieldN/A4.84%4.40%4.10%P/E Ratio-6.431.1830.8325.91Price / SalesN/A26.80469.77121.46Price / CashN/A19.5625.7828.79Price / Book1.806.659.466.03Net Income-$57.56M-$4.94M$3.27B$265.29M7 Day Performance-2.54%1.99%2.37%2.86%1 Month Performance-12.36%2.07%3.88%1.23%1 Year Performance-42.79%12.25%30.52%19.11% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$19.99+1.2%N/A-42.8%$187.87MN/A-6.4390High Trading VolumeTNGXTango Therapeutics1.6082 of 5 stars$6.76+5.5%$10.33+52.9%-40.4%$752.12M$42.07M-5.0890STOKStoke Therapeutics4.5588 of 5 stars$13.53+2.8%$25.80+90.7%+39.8%$738.74M$36.56M17.13100PHATPhathom Pharmaceuticals2.5549 of 5 stars$10.38+1.0%$17.50+68.6%-13.9%$736.36M$55.25M-2.19110AMLXAmylyx Pharmaceuticals3.4005 of 5 stars$8.20+4.9%$11.75+43.3%+317.0%$731.19M$87.37M-3.28200BGMBGM GroupN/A$7.44-2.2%N/A+33.4%$723.32M$25.10M0.00298Positive NewsGYREGyre Therapeutics0.0294 of 5 stars$7.56+6.9%N/A-36.3%$708.83M$105.76M378.1940SANASana Biotechnology2.9517 of 5 stars$3.11+6.5%$8.00+157.2%-38.7%$701.24MN/A-3.53380MRVIMaravai LifeSciences4.0292 of 5 stars$2.69+30.6%$5.75+113.8%-72.5%$685.04M$259.18M-2.36610Gap UpHigh Trading VolumeDNAGinkgo Bioworks1.3378 of 5 stars$11.53-3.0%$8.50-26.3%+53.5%$674.85M$227.04M-1.97640Analyst ForecastSIGASiga Technologies2.3852 of 5 stars$9.30-1.9%N/A-3.8%$665.97M$138.72M8.2340 Related Companies and Tools Related Companies Tango Therapeutics Alternatives Stoke Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Amylyx Pharmaceuticals Alternatives BGM Group Alternatives Gyre Therapeutics Alternatives Sana Biotechnology Alternatives Maravai LifeSciences Alternatives Ginkgo Bioworks Alternatives Siga Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access